<DOC>
	<DOCNO>NCT02307812</DOCNO>
	<brief_summary>The treat physician/investigator contact Lilly , base medical opinion , patient meet criteria inclusion ATU .</brief_summary>
	<brief_title>Ramucirumab Use Combination With Paclitaxel Gastric Gastroesophageal Junction Adenocarcinoma ; Temporary Authorization Use ( ATU ) France</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>The participant histologically cytologically confirm gastric adenocarcinoma , include gastroesophageal junction ( GEJ ) adenocarcinoma ( Participants adenocarcinoma distal esophagus eligible primary tumor involve GEJ . ) prior chemotherapy . Acceptable prior chemotherapy regimen protocol combination chemotherapy regimens include platinum fluoropyrimidine component ( acceptable prior platinum agent cisplatin , carboplatin , oxaliplatin ; acceptable prior fluoropyrimidine agent 5fluorouracil ( 5FU ) capecitabine ) . Prior trastuzumab use human epidermal growth factor receptor 2 positive ( HER2+ ) participant accept . The participant eligible treatment chemotherapy Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 0 1 . Participant know allergy treatment component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>